Results 321 to 330 of about 589,804 (355)
Some of the next articles are maybe not open access.
Discovery and Development of Dolastatin 10-Derived Antibody Drug Conjugate Anticancer Drugs.
Journal of Natural Products, 2022Dolastatin 10 is an extremely potent broad-spectrum antitubulin anticancer pentapeptide isolated from Dolabella auricularia. The two-dimensional structure was elucidated by NMR and mass spectrometric analyses. The absolute configuration was determined by
Sheo B. Singh
semanticscholar +1 more source
Antibody-Drug Conjugate Targets, Drugs and Linkers.
Current Cancer Drug Targets, 2022Antibody-drug conjugates offer the possibility of directing powerful cytotoxic agents to a malignant tumor while sparing normal tissue. The challenge is to select an antibody target expressed exclusively or at highly elevated levels on the surface of ...
B. Teicher, Joel Morris
semanticscholar +1 more source
Science Translational Medicine, 2021
CLDN6 is not only a marker of hepatocellular carcinoma but also a therapeutic target by promoting sorafenib resistance and lineage plasticity. Targeting tumor lineage plasticity Lineage plasticity allows tumor cells to evolve during anticancer treatment,
Fan-En Kong+18 more
semanticscholar +1 more source
CLDN6 is not only a marker of hepatocellular carcinoma but also a therapeutic target by promoting sorafenib resistance and lineage plasticity. Targeting tumor lineage plasticity Lineage plasticity allows tumor cells to evolve during anticancer treatment,
Fan-En Kong+18 more
semanticscholar +1 more source
What makes a good antibody–drug conjugate?
Expert Opinion on Biological Therapy, 2021Introduction: Antibody-Drug Conjugates (ADCs) are becoming increasingly important weapons in the fight against cancer, as evidenced by the growing number of approved products.
Martin De Cecco+2 more
semanticscholar +1 more source
Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy.
Journal of Medicinal Chemistry, 2021Antibody-drug conjugate (ADC) and immune checkpoint blockade (ICB) offer promising approaches for cancer treatment. Here, we describe an ADC constructed by conjugating anti-PD-L1 THIOMAB with a bifunctional immunomodulator D18 via a redox-cleavable ...
Lei He+9 more
semanticscholar +1 more source
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy
Expert Opinion on Biological Therapy, 2020Introduction We describe a new, third-generation of antibody-drug conjugates (ADCs) having a high drug payload against topoisomerase I, important for DNA function, and targeting selective tumor antigens, predominantly TROP-2. Areas Covered The historical
D. Goldenberg, R. Sharkey
semanticscholar +1 more source
Antibody Glycoengineering and Homogeneous Antibody‐Drug Conjugate Preparation
The chemical record, 2021Antibody‐drug conjugates (ADCs) are a class of biopharmaceuticals in which cytotoxic agents are conjugated to monoclonal antibodies (mAbs), allowing targeted drug delivery.
S. Manabe, Y. Yamaguchi
semanticscholar +1 more source
Antibody-Drug Conjugate-Based Therapeutics: State of the Science.
Journal of the National Cancer Institute, 2019Antibody-drug conjugates (ADCs) are complex engineered therapeutics consisting of monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent cytotoxic agents are attached using chemical linkers.
M. Birrer+3 more
semanticscholar +1 more source
The Annals of Pharmacotherapy, 2020
Objective: To review the pharmacology, efficacy, and safety of sacituzumab govitecan (-hziy; IMMU-132, Trodelvy) for patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease.
J. Seligson+4 more
semanticscholar +1 more source
Objective: To review the pharmacology, efficacy, and safety of sacituzumab govitecan (-hziy; IMMU-132, Trodelvy) for patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease.
J. Seligson+4 more
semanticscholar +1 more source
Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy
Journal of Cellular Physiology, 2019Cytotoxic small‐molecule drugs have a major influence on the fate of antibody–drug conjugates (ADCs). An ideal cytotoxic agent should be highly potent, remain stable while linked to ADCs, kill the targeted tumor cell upon internalization and release from
S. Yaghoubi+10 more
semanticscholar +1 more source